Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, Inscripta is raising $149,999,970.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sri Kosaraju played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inscripta

Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations.  Inscripta is backed by leading investors including Venrock, Foresite, Paladin Capital Group, Mrieux Dveloppement, NanoDimension, MLS Capital, JS Capital Management LLC, and Oak HC/FT.

To learn more about Inscripta, visit http://www.inscripta.com/

Contact:
Sri Kosaraju, Chief Executive Officer
720-759-4088
https://www.linkedin.com/in/sri-kosaraju-a0a8051aa/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved